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INTRODUCTION 
Despite a decline in incidence over the last decade, gastric cancer (GC) remains a 
major cause of global cancer mortality[1]. GC is particularly common in Asian 
countries[2] with the highest incidences reported in South Korea and Japan[3]. 
Amplification of receptor tyrosine kinases (RTKs) such as EGFR, HER2, FGFR2 and 
MET has been associated with GC pathogenesis and tumour progression[4-7]. 
Recent studies including our own seem to indicate that RTK gene amplification in 
primary GC (primGC) occurs in a mutually exclusive manner suggesting that 
targeting an individual RTK may be an effective treatment[8-10]. The ToGA trial 
demonstrated benefit from HER2 targeted treatment using trastuzumab in patients 
with HER2 positive metastatic GC[11 12]. However, all other currently available 
HER2, EGFR and MET targeted drugs (lapatinib, T-DM1, cetuximab, panitumumab, 
rilotumumab, and onartuzumab) have been less successful in GC patients raising the 
question about potential mechanisms of resistance against RTK targeted therapy[13 
14].  
 
Based on recent studies in colorectal cancer[15 16], breast cancer[17-19] and non-
small cell lung cancer cell lines[20 21], one suggested potential resistance 
mechanism could be co-existing amplifications of genes located downstream of RTK 
such as KRAS, PIK3CA, CCNE1 and MYC (collectively called downstream signalling 
(DSS) genes from hereon)[15-20 22]. In GC cell lines, co-amplification of MET and 
KRAS was related to resistance to MET inhibitors and MET amplification to 
resistance to the HER2 and EGFR targeted drug lapatinib[23]. Furthermore, co-
amplification of EGFR and HER2 has been associated with HER2 targeted therapy 
resistance in GC[24].  
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A second potential resistance mechanism could be related to genetic heterogeneity 
resulting in a discordant gene copy number status between primary cancer and 
metastatic site[25] as reported recently in cancers of breast[26], colorectal[27], 
renal[28], larynx/pharynx[29] and liver[30]. In GC, up to 10% discordance of HER2 
gene copy number status between primGC and matched lymph node metastasis has 
been reported[31 32] and was related to poorer prognosis[33]. However, the 
concordance of the gene copy number status between primGC and matched lymph 
node metastasis (LNmet) has not been investigated for other RTKs or DSSs and 
there are no studies evaluating the presence of RTK and DSS gene co-amplifications 
in this context.  
 
We hypothesised that (1) co-amplification of RTK (HER2, EGFR, MET, FGFR2) and 
DSS (PIK3CA, KRAS, CCNE1, MYC) is a common phenomenon in primGC, (2) 
patients with co-amplification of RTK and DSS in the primGC have the poorest 
overall survival, and that (3) the RTK and DSS gene copy number status will only be 
discordant between primGC and their matched LNmet in a minority of patients.   
 
The aim of this study was to develop a new multiplex ligation-dependent probe 
amplification (MLPA) probemix for the simultaneous assessment of RTKs (EGFR, 
FGFR2, MET, HER2) and DSSs (KRAS, PIK3CA, CCNE1, MYC) gene copy number 
status using DNA extracted from formalin fixed paraffin embedded tissue of primGC 
and matched LNmet and to establish the relationship between RTKs and DSSs gene 
copy number status with clinicopathological data and patient survival. 
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MATERIAL AND METHODS 
Patients 
After quality control, results were available from 237 patients with TNM 7th ed [34] 
stage II/III/IV gastric cancer who underwent potentially curative surgery at the 
Kanagawa Cancer Center Hospital (KCCH, Yokohama, Japan) between 2001 and 
2010. 101 (43%) patients were treated by surgery alone and 136 by surgery and 
adjuvant cytotoxic chemotherapy. None of the patients included in this study received 
targeted therapy. Demographical and clinicopathological data including depth of 
invasion (pT category), lymph node status (pN category), distant metastasis (pM 
category), histological subtype according to Lauren classification[35] and tumour 
location according to the Japanese classification[36] were retrieved from local 
hospital records. Patient follow-up data and other parameters were obtained from 
histopathology reports and hospital records. Median follow-up time from surgery was 
3.5 years, ranging from 0.3 to 9.5 years. This study was approved by the Local 
Research Ethics Committee. 
 
Gastric cancer cell lines 
DNA from 13 GC cell lines (CLS145, HS746T, KATOIII, MKN1, MKN7, NCI-N87, 
NUGC4, SNU16, YCC1, YCC11, YCC3, YCC7 and YCC9) with previously described 
gene copy number status[9] was extracted using the Qiagen genomic DNA extraction 
kit (Qiagen, Hilden, Germany) according to the instructions of the manufacturer and 
used to assess the sensitivity and specificity of the newly developed Multiplex 
Ligation Probe Amplification (MLPA) probemix. 
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DNA was extracted from eight EDTA blood samples from healthy human donors 
using the Qiagen DNAeasy Blood and Tissue kit (Qiagen, Hilden, Germany) 
according to the instructions of the manufacturer and used as reference sample for 
the GC cell lines in the MLPA probemix.  
 
DNA Extraction from gastric cancer tissue samples 
All Haematoxylin/Eosin stained slides from all 241 formalin fixed paraffin embedded 
(FFPE) gastrectomy specimens were reviewed. From all patients, a block from the 
primary tumour with the highest number of tumour cells per area was selected. From 
128 patients with regional lymph node metastases, a block from the lymph node 
metastasis with the highest number of tumour cells per area was selected. DNA 
extraction was performed as described previously[37]. DNA concentration was 
measured by ND-100 Spectrophotometer (Labtech International) and adjusted to a 
final concentration of 100ng/µl. DNA from 12 normal FFPE tonsils was extracted 
using the same method, pooled and used as reference sample in the MLPA 
probemix.  
 
MLPA experiment  
The MLPA protocol by Schouten et al [38] was slightly modified by increasing the 
number of PCR cycles from 33 to 35. MLPA probemix and reagents (Salsa MLPA 
reagent kit, Salsa PCR reagents, Salsa polymerase, Ligase-65) were developed and 
supplied by MRC-Holland b.v., Amsterdam, NL. Each experimental run included DNA 
from GC cell lines, GC tissue (primary GC (primGC) and/or lymph node metastasis 
(LNmet)), reference sample (blood or tonsils), as well as negative controls (no DNA).  
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The first 90 cases were run in duplicates to assess reproducibility of results between 
runs. In 7 out of 720 (1%) of duplicates, there was a different result which would lead 
to a different gene copy number status class. Considering this high degree of 
reproducibility, it was felt that running samples in duplicates for the entire cohort was 
unnecessary. 
 
The MLPA reaction product was sequenced on an ABI 3130 XL Sequencer (ABI 
Biosystems, California, USA). The output files from the sequencer (FSA files) were 
imported into Coffalyser.Net software version 130202.2357 [39] for analysis. 
Samples with a Coffalyser analysis score (CAS) of less than 50% were considered to 
be of poor quality and excluded from further analyses. Failed experiments were 
repeated at least twice before a case was finally excluded from the analyses. Four 
primGC and fifteen LNmet had to be excluded following Coffalyser quality control 
analysis (Figure 1).  
 
Reference samples (DNA from blood or tonsils as appropriate) with a CAS of 100% 
were used to determine the normal range of values for the peak height recognition. 
Based on the results from our normal reference samples and in accordance with 
previously published studies[40 41], we set the thresholds as follows: a gene copy 
number ratio of less than 0.80 was categorised as ‘loss’, between 0.80-1.30 as 
‘normal’, between 1.31-2.00 as ‘low level amplification’, between 2.01-5.00 as ‘high 
level amplification’ and above 5.00 as ‘very high level amplification’.  
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MLPA assay  
For further details on the MLPA probemix development, data analysis, use of 
competitor mixes for very highly amplified genes and studies to validate the assay, 
see supplementary document Table S1, S2 and Figure S1.  
 
Statistical analyses  
Statistical analyses were performed using PASW Statistics 21 (IBM Corporation, 
New York, USA) analysing the gene copy number status of receptor tyrosine kinases 
(RTKs) EGFR, FGFR2, MET, HER2 and downstream signalling pathway genes 
(DSSs) KRAS, PIK3CA, CCNE1 and MYC. All analyses described below were 
performed separately for primGC and LNmet. PrimGC or LNmet with low, high and 
very high level amplification (see MLPA experiment description above) were grouped 
together as ‘amplification’ and compared to samples with deletion or normal gene 
copy number status.   
 
Co-amplification was defined as two or more genes having a gene copy number ratio 
>1.30. The Chi-squared test was used to analyse the relationship between gene copy 
number statuses of different genes. The relationship between gene copy number 
status and clinicopathological variables in the primGC and gene copy number status 
in the LNmet was analysed using the Kruskal-Wallis test. 
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For survival analyses, primGC or LNmet with a gene copy number ratio of all RTK 
genes ≤1.30 were classified as ‘no RTK amplification’, with a gene copy number ratio 
of a single RTK gene >1.30 were classified as ‘RTK amplification’ and those with a 
gene copy number ratio of more than one RTK gene >1.30 were classified as ‘RTK 
co-amplification’. The same classification was used for DSS gene copy number 
status. GC with ‘no DSS amplification + no RTK amplification’ were compared to GC 
with ‘no DSS amplification + RTK amplification’, ‘DSS amplification + no RTK 
amplification’, as well as with ‘DSS amplification + RTK amplification’. 
 
In cases with amplifications, the status of the amplified gene(s) was compared 
between primGC and LNmet to identify so called ‘conversion’: (1) negative 
conversion was defined as gene amplification (copy number >1.30) detectable in the 
primGC which was not detectable in the matched LNmet; (2) positive conversion was 
defined as gene amplification detectable in the LNmet which was not detectable in 
the matched primGC; (3) no conversion was defined as gene amplification detectable 
in both, primGC and LNmet. Univariate survival analyses were performed using the 
Kaplan Meier method and log rank test. Multivariate analyses was performed using 
Cox regression proportional hazard model including TNM stage and variable of 
interest in the model. P values of less than 0.05 were considered significant.   
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RESULTS 
MLPA analysis of gene copy number status in primary gastric cancer (primGC) 
Results from 237 primGC were available for final analyses (Figure 1). The median 
(range) age of the study cohort was 65 years (35 to 85 years), for details on patients’ 
characteristics see Table 1. 
 
In primGC, the most frequently amplified gene was PIK3CA (n=60, 25%) followed by 
KRAS (n=47, 20%), MYC (n=44, 19%), HER2 (n=42, 18%), CCNE1 (n=39, 16%), 
EGFR (n=25, 10%), FGFR2 (n=24, 10%) and MET (n=11, 4%). For details on the 
frequency of normal gene copy number and losses see supplementary document 
Table S3.  
 
MLPA analysis of gene copy number status in lymph node metastasis (LNmet)  
Results from 103 LNmet were available for final analyses (Figure 1). In LNmet, the 
most frequently amplified gene was MYC (n=27, 26%) followed by PIK3CA (n=18, 
18%), KRAS (n=12, 11%), CCNE1 (n=9, 9%), HER2 (n=7, 7%), FGFR2 (n=7, 7%), 
EGFR (n=5, 5%) and MET (n=2, 2%). For details on the frequency of normal gene 
copy number and losses see supplementary document Table S3.  
 
RTK and DSS gene co-amplification in primary gastric cancer 
There were 86 (36%) primGC with neither DSS nor RTK amplification, 74 (31%) 
primGC with DSS amplification without RTK co-amplification, 25 (11%) primGC with 
RTK co-amplification without DSS co-amplification and 52 (22%) primGC had co-
amplification of RTK and at least one DSS (Table 2).  
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Co-amplification of DSS genes was present in 48 (20%) primGC and was more 
common than RTK co-amplifications (n=21, 9%). High level co-amplification (gene 
copy number > 2.00) of RTK was not detected and was rare for DSS (n=4, 2%). For 
details about the frequency of co-amplification of individual genes see Venn diagram 
supplementary document Figure S2. 
 
RTK and DSS gene co-amplification in lymph node metastasis 
There were 45 (44%) LNmet with neither DSS nor RTK amplification, 39 (37%) 
LNmet with DSS amplification without RTK co-amplification, 9 (9%) LNmet with RTK 
amplification without DSS co-amplification and 10 (10%) LNmet had co-amplification 
of RTK and at least one DSS (Table 2). Co-amplification of DSS genes was present 
in 14 (14%) LNmet and was more common than RTK co-amplifications (n=2, 2%). 
High level co-amplification (gene copy number > 2.00) of RTK occurred in one LNmet 
(1%) and of DSS in two LNmet (2%). 
 
Comparison of gene copy number status between primary gastric cancer and 
matched lymph node metastasis   
70 (68%) of the 103 patients with results from primGC and matched LNmet showed 
‘conversion’. When comparing gene copy number status of individual genes between 
primGC and matched LNmet, there was a significant difference for KRAS (p<0.001), 
MYC (p<0.001), CCNE (p<0.001), HER2 (p=0.005) and FGFR2 (p<0.001), whereas  
PIK3CA, EGFR and MET gene copy number status was similar (all p-values > 0.5). 
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Considering all RTK and DSS genes together, 15 (21%) patients had positive 
(primGC not amplified, LNmet amplified) and negative conversions (primGC 
amplified, LNmet not amplified), 38 (54%) had negative conversions only and 17 
(24%) had positive conversions only.  
 
Considering RTK genes only, a total of 33 (32%) patients had a conversion: 2 (6%) 
had positive and negative conversions, 25 (76%) had negative conversions only and 
6 (18%) had positive conversions only.  
 
Considering DSS genes only, a total of 56 (54%) patients had a conversion: 10 
(19%) had positive and negative conversions, 30 (54%) had negative conversions 
only, and 16 (29%) had positive conversions only.  
 
Frequencies of conversion per individual gene are shown in Table 3.  
 
Relationship between gene copy number status and clinicopathological 
variables  
EGFR, HER2, MYC and CCNE1 amplification in the primGC was more frequent in 
intestinal type GC (p=0.001, p=0.005, p=0.009 and p=0.001, respectively). MET 
amplification in the primGC was more frequently seen in GC with higher TNM stage 
(p=0.001). PIK3CA amplification was more frequently seen in GC with higher pT 
category (p=0.015), Table 4A and 4B. 
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Relationship between gene copy number status and overall survival  
Patients with RTK amplification in the primGC had a significantly worse survival than 
patients without RTK amplification (p=0.040, Figure 2A). However, multivariate 
analyses including primGC RTK gene copy number status (RTK amplification versus 
no RTK amplification) and TNM stage in the model showed that primGC RTK copy 
number status was not an independent prognostic marker (Hazard ratio:1.457 
95%Confidence interval:  0.995-2.135, p=0.053). 
 
There was no significant survival difference for GC patients with or without DSS 
amplification in the primGC (p=0.153, Figure 2B).  
There was no significant survival difference when patients were stratified by 
presence or absence of DSS and RTK co-amplifications in the primGC (p=0.150, 
Figure 2C). 
 
There was no significant survival difference for patients with or without RTK 
amplification, with or without DSS amplifications or with or without DSS and RTK co-
amplifications in the LNmet (all p-values > 0.05, Figure 3).  
 
There was no significant survival difference between GC patients with or without RTK 
and/or DSS conversion. There was also no survival difference when patients were 
stratified by the type of conversion (p-value 0.296, Figure 4).
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DISCUSSION  
Recent studies including our own[9] suggest that approximately one third of gastric 
adenocarcinomas have mutually exclusive amplification of targetable receptor 
tyrosine kinases (EGFR, HER2, FGFR2, MET)[9 10]. Pre-clinical and clinical studies 
suggest that (1) co-amplification of receptor tyrosine kinase genes (RTK) and 
downstream signalling (DSS) genes could potentially alter targeted therapy efficacy 
[22 23] and that (2) gene copy number status discordance between primary tumour 
and metastases may influence response to RTK targeted treatment[31-33]. Currently, 
very little is known about the frequency of RTK and DSS co-amplification and 
concordance of gene copy number status between primary gastric cancer (primGC) 
and matched lymph node metastasis (LNmet).  
 
As part of this study we designed a new multiplex ligation probe-dependent 
amplification (MLPA) probemix to allow simultaneous assessment of the gene copy 
number status of multiple RTKs and DSSs genes in DNA extracted from formalin 
fixed paraffin embedded gastric cancer specimens in a single experiment[42 43]. Our 
validation studies demonstrated a high level of reproducibility, specificity and 
sensitivity and a low 11/366 (3%) technical dropout rate suggesting that the newly 
developed MLPA assay could be a clinically useful routine screening method to 
assess RTK and DSS gene copy number status.  
 
Our study confirmed previous reports [9 10] that approximately 30% GC have at least 
one RTK amplified and that the presence of RTK amplification in the primary tumour 
is associated with poorer survival (Figure 2A).  
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The co-amplification frequency of HER2 and EGFR, HER2 and MET, as well as of 
FGFR2 and MET in the current study is similar to that reported previously[9 44-46]. 
Furthermore, our study confirmed that high level RTK co-amplifications are mutually 
exclusive events as reported previously[9 10]. In addition, we found that low level 
RTK co-amplifications can occur, which may explain some of the inconsistencies 
reported in the literature[9 44-46] where the definition of what constitutes an 
amplification varies, see supplementary document Table S4. The current study 
supports the previously reported finding that amplification of EGFR, HER2, MYC and 
CCNE1 is more frequent in intestinal type GC[47] [48].  
 
This is the first study to demonstrate that RTK and DSS co-amplification is a common 
event in primary GC. Importantly, this is the first study to identify a substantial 
subgroup of GC patients (36%) with neither RTK nor DSS amplification suggesting 
that there is a subgroup of GC patients where the ERK/MAPK pathway may not be 
the main oncogenic driver. This finding is of potential clinical relevance as patients 
without RTK amplification in their primary GC had better overall survival and thus 
might require a different therapy approach. 
 
Finally, this is the most comprehensive study in GC investigating the concordance 
between the gene copy number statuses of targetable receptor tyrosine kinases and 
downstream signalling oncogenes in primary tumour and matched lymph node 
metastasis demonstrating that the gene copy number status of the majority of 
investigated genes differs in up to 68% GC between the primGC and the LNmet.  
However the conversion of RTK or DSS genes does not appear to influence survival 
(Figure 4).  
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The HER2 gene copy number status concordance between primGC and LNmet is 
lower in the current study than reported in a recent meta-analysis[49]. Nevertheless, 
the meta-analysis also showed a higher negative than positive conversion rate as 
demonstrated in the current study. These different results could be related to 
differences in case mix, number of investigated cases per study, patient ethnicity as 
well as to the use of different experimental platforms to assess HER2 gene copy 
number status. Whilst there is good evidence supporting similar specificity and 
sensitivity of the MLPA assay compared to the FISH method[40 50], the MLPA assay 
is unable to distinguish between polysomy and amplification which could explain our 
relatively higher frequencies in comparison to the current literature.  
 
The results from selected RTK and DSS gene copy number analyses in our study 
support the current model hypothesis that metastatic tumour cells in the lymph node 
may constitute a cell population with a different genetic makeup compared to the 
matched primary tumour. The clinically undetected ‘loss’ of an amplification of a RTK 
gene in a metastatic site which was present in the primary tumour may potentially 
render the targeted drug inefficient. This issue could potentially be addressed by 
investigating the gene copy number status in the primary tumour as well as in the 
metastatic site.  
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This study has some limitations. This is a retrospective study and thus we were 
unable to assess the clinical relevance of co-amplifications of RTK and DSS with 
respect to resistance to RTK targeted therapy as patients in this study did not receive 
targeted therapy. Therefore, the predictive value of RTK/DSS co-amplification and/or 
genetic conversion between primary cancer and metastasis in gastric cancer patients 
remains to be investigated.  
 
Furthermore, this study focussed on TNM stage II, III and IV Japanese GC and 
further prospective studies need to demonstrate that the results from this study can 
be reproduced in GC from patients with other disease stages and/or ethnicities.  
 
On the other hand, our study demonstrated that assessment of the gene copy 
number status of multiple selected genes is feasible with DNA from FFPE material 
(e.g. routine histopathological material), in a timely fashion at relative low cost with 
high sensitivity, specificity and excellent reproducibility using the new developed 
MLPA assay.  
 
In conclusion, the emergence of targeted therapy acquired resistance mechanisms 
requires the development of clinically applicable and affordable methods screening 
for the drug targets as well as for genes related to the same pathway or other 
potential mechanisms that may impact drug effectiveness. This is the first study in 
gastric cancer demonstrating that co-amplification of receptor tyrosine kinase (RTK) 
genes and downstream signalling (DSS) genes is more frequent than RTK 
amplification alone and that conversion of gene copy number status between primary 
GC and matched lymph node metastasis is more frequent than no conversion.  
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As patients in this study did not receive targeted therapy, we can currently only 
speculate that RTK and DSS co-amplification in GC as well as discordance of gene 
copy number status between primary tumour and lymph node metastases in GC 
could potentially explain the recently seen failures of EGFR and MET targeted 
therapy in GC. Future studies are needed to investigate whether GC patients 
considered for RTK targeted therapy require gene copy number assessment of 
receptor tyrosine kinase genes as well as downstream signalling genes from primary 
tumour and lymph node metastasis to identify potential responders.    
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FIGURE LEGENDS  
Figure 1  Flow diagram detailing how the final number of primary gastric cancer and 
matched lymph node metastasis available for analyses was reached.  
 
Figure 2. Kaplan Meier plots showing probability of overall survival stratified by 
receptor tyrosine kinase gene (RTK) and/or downstream signalling gene (DSS) copy 
number status in the primary gastric cancer. 
A. Kaplan Meier survival analysis showed that gastric cancer patients without RTK 
gene amplification in their primary tumour survived significantly longer than patients 
with at least one amplified RTK gene.  
B. Kaplan Meier survival analysis showed no difference in overall survival when 
patients were stratified by DSS gene copy number status of the primary tumour.  
C. Kaplan Meier survival analysis showed no difference in overall survival when 
patients were stratified by combining the RTK and DSS gene copy number status of 
the primary tumour. Key: (+) = amplification, (-) = no amplification. 
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Figure 3. Kaplan Meier plots showing probability of overall survival by receptor 
tyrosine kinase gene (RTK) and/or downstream signalling gene (DSS) copy number 
status in the lymph node metastasis. 
A. Kaplan Meier survival analysis showed no difference in overall survival when 
patients were stratified by RTK gene copy number status of the lymph node 
metastasis. 
B. Kaplan Meier survival analysis showed no difference in overall survival when 
patients were stratified by DSS copy number status of the lymph node metastasis. 
C. Kaplan Meier survival analysis showed no difference in overall survival when 
patients were stratified by combining the RTK and DSS gene copy number status of 
the primary tumour. Key: (+) = amplification, (-) = no amplification. Key: (+) = 
amplification, (-) = no amplification. 
 
Figure 4. Kaplan Meier plots showing probability of overall survival by gene copy 
number conversion.   
Considering the gene copy number status of all RTK and DSS genes, Kaplan Meier 
survival analysis showed no difference in overall survival between patients with and 
without gene copy number conversion between primary tumour and lymph node 
metastasis.  
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Table 1.  
Clinicopathological characteristics of the gastric cancer patient cohort (n=237) and the subgroup 
of patients with lymph node metastasis (Lnmet, n=103) 
 
 
Gastric cancer cohort 
Gastric cancer subgroup with 
LNmet  
 n  % n  % 
Gender 
Male  
Female 
166 
71 
70 
30 
75 
28 
73 
27 
Tumour location   
Proximal 
Mid 
Distal 
71 
97 
69 
30 
41 
29 
28 
41 
34 
27 
40 
33 
Depth of invasion (pT)   
pT1b 
pT2 
pT3 
pT4a 
6 
43 
31 
157 
3 
18 
13 
66 
1 
21 
13 
68 
1 
20 
13 
66 
Lymph node status (pN)   
pN0 
pN1 
pN2 
pN3a 
pN3b 
37 
58 
63 
61 
18 
16 
24 
27 
26 
7 
0 
22 
29 
42 
10 
0 
21 
28 
41 
10 
Distant metastasis (pM)   
pM0 
pM1(peritoneal) 
226 
11 
95 
5 
98 
5 
95 
5 
TNM stage 7th Edition    
II 
III 
IV 
93 
133 
11 
39 
56 
5 
24 
74 
5 
23 
72 
5 
Histological tumour type (Lauren)    
Intestinal  
Diffuse  
111 
126 
47 
53 
58 
45 
56 
44 
 
 
  
   
Table 3. 
Frequency of conversion between primary gastric cancer (primGC) and matched lymph node 
metastasis (LNmet) by individual gene. 
Gene Amplified in primGC,  
not amplified in LNmet 
(negative conversion) 
 n (%) 
Amplified in primGC 
and amplified in LNmet 
(no conversion) 
n (%) 
Not amplified in primGC 
 and amplified in LNmet  
(positive conversion) 
n (%) 
EGFR 8 (9) 2 (4)  3 (8) 
HER2 17 (20) 5 (10) 2 (5) 
FGFR2 7 (8) 4 (8) 3 (8) 
MET 4 (5) 1 (2) 1 (3) 
PIK3CA 22 (25) 9 (18)  10 (27) 
KRAS  9 (10) 9 (18) 3 (8) 
CCNE 14 (16) 8 (16) 1 (3) 
MYC 6 (7) 13 (25) 14 (38) 
Table 2. 
Frequency of Receptor Tyrosine Kinases (RTK) and Downstream Signalling (DSS) gene 
amplification in primary gastric cancer (primGC) and lymph node metastasis (LNmet).   
 No RTK amplification  RTK amplification  
primGC 
n (%) 
LNmet 
n (%) 
primGC 
n (%) 
LNmet 
n (%) 
No DSS amplification             86 (54) 45 (54)  25 (32) 9 (47) 
DSS amplification                  74 (46) 39  (46) 52 (68) 10 (53) 
  
Table 4A.  
Relationship of  primary gastric cancer receptor tyrosine kinases gene copy number status and clinicopathological variables 
 RTK gene 
EGFR 
 
p-value 
HER2 
 
p-value 
FGFR2 
 
p-value 
MET 
 
p-value 
Amplified 
n (%) 
Not 
amplified 
n (%) 
Amplified 
n (%) 
Not 
amplified 
 n (%) 
Amplified 
n (%) 
Not 
amplified 
n (%) 
Amplified 
n (%) 
Not 
amplified 
n (%) 
Gender 
Male 
Female 
20 (80) 
5 (20) 
146 (70) 
66 (30) 
0.251 
30 (71) 
12 (29) 
136 (70) 
59 (30) 
0.829 
18 (75) 
6 (25) 
148 (69) 
65 (31) 
0.577 
7 (63) 
4 (37) 
159 (70) 
67 (30) 
0.636 
Depth of invasion (pT) 
pT1b 
pT2 
pT3 
pT4a 
0 (0) 
3 (12) 
1 (4) 
21 (84) 
6 (3) 
40 (19) 
30 (14) 
136 (64) 
0.225 
1 (2) 
7 (17) 
5 (12) 
29 (70) 
5 (3) 
36 (18) 
26 (13) 
128 (6) 
0.981 
0 (0) 
3 (13) 
5 (21) 
16 (66) 
6 (3) 
40 (19) 
26 (12) 
141 (66) 
0.501 
0 (0) 
2 (18) 
1 (9) 
8 (73) 
6 (3) 
41 (18) 
30 (13) 
149 (66) 
0.918 
Lymph node status (pN) 
pN0 
pN1 
pN2 
pN3a 
pN3b 
4 (16) 
6 (24) 
6 (24) 
7 (28) 
2 (4) 
33 (16) 
52 (25) 
57 (27) 
54 (25) 
16 (7) 
0.998 
8 (19) 
9 (21) 
10 (24) 
11 (26) 
4 (10) 
29 (15) 
49 (25) 
53 (27) 
50 (26) 
14 (7) 
0.913 
4 (17) 
5 (21) 
8 (33) 
3 (12) 
4 (17) 
33 (15) 
53 (25) 
55 (26) 
58 (27) 
14 (7) 
0.257 
1 (9) 
1 (9) 
6 (55) 
1 (9) 
2 (18) 
36 (16) 
57 (25) 
57 (25) 
60 (27) 
16 (7) 
0.102 
Distant metastasis (pM) 
pM0 
pM1 
25 (100) 
0 (0) 
201 (95) 
11 (5) 
0.875 
41 (98) 
1 (2) 
185 (95) 
10 (5) 
0.444 
23 (96) 
1 (4) 
203 (95) 
10 (5) 
0.907 
8 (73) 
3 (27) 
218 (96) 
8 (4) 
<0.001 
TNM stage 
Stage II 
Stage III 
Stage IV 
7 (28) 
18 (72) 
0 (0) 
85 (40) 
116 (55) 
11 (5) 
0.191 
15 (36) 
26 (62) 
1 (2) 
77 (40) 
108 (55) 
10 (5) 
0.624 
8 (33) 
15 (63) 
1 (4) 
84 (39) 
119 (56) 
10 (5) 
0.824 
2 (18) 
6 (55) 
3 (27) 
90 (39) 
128 (57) 
8 (4) 
0.001 
Histological tumour type (Lauren) 
Intestinal  
Diffuse  
19 (80) 
5 (20) 
88 (42) 
121 (58) 
0.001 
27 (66) 
14 (34) 
80 (42) 
112 (68) 
0.005 
11 (46) 
13 (54) 
96 (46) 
113 (54) 
0.993 
6 (55) 
5 (45) 
101 (44) 
121 (56) 
0.557 
  
Table 4B.  
Relationship of primary gastric cancer downstream signalling gene copy number status and clinicopathological variables.  
 DSS Genes 
PIK3CA 
 
p-value 
KRAS 
 
p-value 
MYC 
 
p-value 
CCNE1 
 
p-value 
Amplified 
n (%) 
Not 
amplified 
n (%) 
Amplified 
n (%) 
Not 
amplified 
n (%) 
Amplified 
n (%) 
Not 
amplified 
n (%) 
Amplified 
n (%) 
Not 
amplified 
n (%) 
Gender  
Male 
Female 
48 (80) 
12 (20) 
118 (66) 
59 (34) 
0.052 
33 (70) 
14 (30) 
133 (70) 
57 (30) 
0.977 
34 (77) 
10 (23) 
132 (68) 
61 (32) 
0.247 
29 (74) 
10 (26) 
137 (69) 
61 (31) 
0.423 
Depth of invasion (pT) 
pT1b 
pT2 
pT3 
pT4a 
1 (2) 
8 (13) 
14 (23) 
37 (62) 
5 (3) 
35 (20) 
17 (10) 
120 (67) 
0.047 
1 (2) 
8 (17) 
9 (19) 
29 (62) 
5 (3) 
35 (18) 
22 (12) 
128 (67) 
0.593 
1 (2) 
9 (20) 
6 (14) 
28 (64) 
5 (3) 
34 (18) 
25 (13) 
129 (66) 
0.971 
1 (3) 
8 (21) 
11 (28) 
19 (48) 
5 (3) 
35 (18) 
20 (10) 
138 (69) 
0.015 
Lymph node status (pN) 
pN0 
pN1 
pN2 
pN3a 
pN3b 
7 (12) 
13 (22) 
18 (30) 
18 (30) 
4 (6) 
30 (17) 
45 (25) 
45 (25) 
43 (24) 
14 (9) 
0.724 
7 (15) 
15 (32) 
12 (26) 
10 (21) 
3 (6) 
30 (16) 
43 (23) 
51 (27) 
51 (27) 
15 (7) 
0.749 
7 (16) 
11 (25) 
11 (25) 
12 (27) 
3 (7) 
30 (16)  
47 (24) 
52 (27) 
49 (25) 
15 (8) 
0.997 
4 (10) 
15 (38) 
10 (26) 
8 (21) 
2 (5) 
33 (17) 
43 (22) 
53 (27) 
53 (27) 
16 (7) 
0.244 
Distant metastasis (pM) 
pM0 
pM1 
59 (98) 
1 (2) 
167 (94) 
10 (6) 
0.206 
43 (91) 
4 (9) 
183 (96) 
7 (4) 
0.160 
42 (95) 
2 (5) 
184 (95) 
9 (5) 
0.973 
37 (95) 
2 (5) 
189 (95) 
9 (5) 
0.875 
TNM stage 
Stage II 
Stage III 
Stage IV 
21 (35) 
38 (63) 
1 (2) 
71 (40) 
96 (54) 
10 (6) 
0.290 
18 (38) 
25 (53) 
4 (9) 
74 (39) 
109 (57) 
7 (4) 
0.367 
16 (36) 
26 (59) 
2 (5) 
76 (39) 
108 (56) 
9 (5) 
0.929 
18 (46) 
19 (49) 
2 (5) 
74 (37) 
115 (58) 
9 (5) 
0.557 
Histological tumour type (Lauren) 
Intestinal  
Diffuse  
23 (38) 
36 (62) 
84 (48) 
90 (52) 
0.217 
20 (43) 
27 (57) 
87 (47) 
99  (53) 
0.605 
28 (63) 
16 (37) 
79 (42) 
110 (58) 
0.009 
28 (73) 
10 (27) 
79 (41) 
116 (59) 
<0.001 
 Primary gastric 
cancer available   
n=241 
with lymph node 
 metastasis 
n=200  
 Poor quality  
CAS<50% 
n=15 
  Primary gastric 
cancer available 
for analysis 
n=237 
 Yokohama 
GC cohort  
n=251 
No material 
available 
n=10  
Lymph node metastasis 
available 
n=128  
No material  
available 
n=72  
Extraction  
failed 
 n=2 
No matched primary 
GC for comparison  
n=8 
Matched lymph  
node metastasis available  
for analysis   
n=103 
Poor quality 
CAS<50% 
n=4 
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 MLPA probemix development 
For this study, a novel multiplex ligation-dependent probe amplification (MLPA) probemix for GC (P458-A1-lot0312) was designed and optimized 
by MRC-Holland (IZ, JC, SS, MRC Holland, Amsterdam, The Netherlands). The probemix was designed to assess the gene copy number status 
of receptor tyrosine kinase (RTKs: EGFR, HER2, FGFR2 and MET) and downstream signalling genes (DSSs: PIK3CA, KRAS, MYC, and CCNE) 
as well as some other genes. A detailed description of the probemix is provided in supplementary table 1.  
The probes included in this assay were selected either from existing probes from the MRC-Holland MLPA probe database or newly designed by 
MRC-Holland. 13 probes detecting nine different autosomal locations, which have reportedly relatively stable gene copy number status in GC, 
were included in the assay as reference probes for data normalisation. In addition, the MLPA assay contained nine quality control probes to 
assess DNA denaturation status and DNA quantity, as well as probes specific for the X and Y chromosomes.  
  
 
Table S1.  MLPA probe composition of the MRC Holland P458-A1 Gastric cancer probemix 
 Length Probe Gene Chr. band Exon  HG18 location 
Target probes 
427 03827-L21157 PIK3CA 3q26.32 Exon 2 03-180.399605 
259 16057-L21634 PIK3CA 3q26.32 Exon 7 03-180.410094 
214 03826-L22080 PIK3CA 3q26.32 Exon 19 03-180.430490 
418 05435-L20672 EGFR 7p11.2 Exon 2 07-055.177534 
282 05960-L21637 EGFR 7p11.2 Exon 14 07-055.198927 
325 05971-L21639 EGFR 7p11.2 Exon 27 07-055.236403 
196 10314-L22071 MET 7q31.2 Exon 4 07-116.167344 
208 10320-L10834 MET 7q31.2 Exon 10 07-116.186668 
266 02577-L21635 MET 7q31.2 Exon 21 07-116.223340 
166 15894-L21929 MYC 8q24.21 Exon 1 08-128.817870 
156 00580-L21927 MYC 8q24.21 Exon 3 08-128.822148 
331 07631-L21642 FGFR2 10q26.13 Exon 21 10-123.229418 
310 07628-L07312 FGFR2 10q26.13 Exon 16 10-123.237417 
160 07626-L21928 FGFR2 10q26.13 Exon 3 10-123.343235 
202 17597-SP0529-L22061 KRAS 12p12.1 Exon 6 12-025.252102 
382 17605-SP0543-L21602 KRAS 12p12.1 Exon 4 12-025.269833 
392 09507-L22081 KRAS 12p12.1 Exon 3 12-025.271583 
180 17596-L22078 KRAS 12p12.1 Exon 2 12-025.289376 
145 00675-L21512 ERBB2 17q12 Exon 7 17-035.118096 
339 12047-L21640 ERBB2 17q12 Exon 22 17-035.133374 
357 00717-L21644 ERBB2 17q12 Exon 29 17-035.136627 
171 04201-L03537 CCNE1 19q12 Exon 5 19-034.999920 
399 15145-L22082 CCNE1 19q12 Exon 12 19-035.006411 
Reference probes 
190 08838-L08898 DYSF 2p13.2 Exon 57 02-071.763257 
137 05714-L05152 MAL 2q11.1 Exon 2 02-095.077493 
475 03337-L21654 KCNIP4 4p15.31 Exon 10 04-020.343400 
406 10715-L22083 PKHD1 6p12.2 Exon 36 06-051.932638 
220 14933-L16666 LAMA2 6q22.33 Exon 26 06-129.678701 
319 03156-L22075 MYBPC3 11p11.2 Exon 13 11-047.321628 
500 14882-L21656 RPGRIP1 14q11.2 Exon 13 14-020.859956 
490 09772-L21655 SPG11 15q21.1 Exon 11 15-042.705889 
444 11223-L21650 POLG 15q26.1 Exon 21 15-087.662913 
130 13867-L15385 ABAT 16p13.2 Exon 9 16-008.765458 
371 05770-L21374 VPS35 16q11.2 Exon 13 16-045.260343 
304 12619-L22074 RBM11 21q11.2 Exon 2 21-014.513892 
459 06220-L21652 SLC25A18 22q11.21 Exon 1 22-016.423313 
MLPA assay validation studies  
This study used DNA from GC cell lines with previously published SNP array results [9] to assess the sensitivity and specificity of the assay and 
to demonstrate that the assay was able to detect more than one amplification and/or deletions in the same sample. Leeds GC FFPE archival 
material with known FISH dual RTK (HER2 and FGFR2) amplification [40] was used to test the assay in DNA extracted from FFPE. Furthermore, 
two of the MLPA probes are located in the X and Y chromosome. The results from the gender-specific probes were compared to the reported 
gender and used as an additional means of quality control of the assay.  
Gastric cancer cell lines with known gene copy number status 
Thirteen GC cell lines with known gene copy number aberrations were investigated by the newly developed MLPA assay. The MLPA assay 
successfully identified 24 out of 25 gene amplifications previously detected by SNP arrays[9] (Supplementary Table 2). The previously described 
amplification of PIK3CA was not identified in cell line NUGC4. In addition, the MLPA assay identified copy number aberrations not previously 
described by SNP array[9] such as MYC amplification in CLS145, MET amplification in SNU16, EGFR and CCNE1 amplifications in YCC3 and 
PIK3CA amplification in YCC9 GC cell line. These small differences between the MLPA assay and the previous SNP array results can probably 
be explained by different threshold settings during data analyses between the different experimental platforms.  
Gastric cancer tissues with known gene copy number status 
Three GC FFPE tumour samples with previously FISH detected co-amplification of FGFR2 and HER2[40] also demonstrated co-amplification of 
FGFR2 and HER2 by the MLPA assay.  
Gender identification.   
The MLPA assay correctly identified the gender of all 237 patients in this cohort.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S2.  
Comparison of gene copy number status between single nucleotide polymorphism (SNP) array [1] and multiplex ligation dependent probe amplification 
(MLPA, this study) in gastric cancer cell lines.   
Cell Line SNP amplified genes (SNP copy number)[1] MLPA gene copy number ratios (this study) 
HS746T MET (1.57)  >5.00 
KATOIII FGFR2 (2.15) >5.00 
SNU16 MYC (1.08), FGFR2 (1.73) >5.00, >5.00 
YCC1 KRAS (1.91) >5.00 
CLS145 CCNE1 (0.80), ERBB2 (0.45), EGFR (0.45) >3.00, 1.87, 2.17  
MKN1 KRAS (1.36), MYC (0.43) >5.00,  2.12 
MKN7 ERBB2 (1.63), CCNE1 (1.21) >5.00, >3.00 
NUGC4 EGFR (0.87), ERBB2 (0.64), PIK3CA (0.76) >2.00, 2.29, 1.21 
YCC11 EGFR (1.66), MYC (1.41), CCNE1 (0.43) >5.00, >3.00, 1.43 
NCI-N87 ERBB2 (2.08), EGFR (0.58), MYC (0.44) >5.00, 1.99, 1.40 
YCC9 ERBB2 (2.37), MYC (0.59) >5.00, 1.75  
YCC7 ERBB2 (0.61) 1.99 
YCC3 ERBB2 (0.55) 2.30 
MLPA Coffalyser Analyses  
 
After quality control, a comparative analysis with three normalisation cycles was performed using Coffalyser.Net software version 130202.2357. 
In short, in every sample, for every probe, a tumour to normal gene copy number ratio was obtained by dividing the relative peak height for each 
probe in the tumour by the relative value of the same peak in the reference sample (e.g. normal tonsil or normal blood) DNA. The median peak 
height of all probes per gene was used for final analyses. For the analysis of the gene copy number ratio in cases with gene copy number ratio 
>5, the gene copy number ratio of the very highly amplified gene was used together with the gene copy number ratios of the other genes 
following competitive inhibition of the very highly amplified gene (See Figures S1A-S1D).    
 
MLPA competitor mixes for very high level gene amplification 
High level amplification of a gene targeted by a MLPA probe can result in potential ‘false’ low level signals from the other probes due to probes 
competing for the universal primer pair present in the PCR reaction mix. To address this potential problem, so called ‘competitor mixes’ were 
developed by MRC-Holland for all target genes in the MLPA probemix. These competitor mixes contained oligonucleotides identical to the 5’ end 
of the original MLPA probe but only contained part of the original PCR primer sequence. The gene specific competitor mix was added to the 
reaction mix at the start of the experiment resulting in lower amplification efficiency of the highly amplified probes during the PCR reaction, thus 
increasing the amplification efficiency of all other probes. All samples that showed a MLPA gene copy number ratio >5 were reanalysed with the 
appropriate competitor mix. The effect of including the competitor mix on the MLPA reaction is shown in supplementary figures 1A-1D.  
 
 
 
Figure S1A 
 
Figure S1A  Data output from the GC cell line mix following comparative analysis in Coffalyser Software.  The column contains the sample name and the row 
has the information on copy number status per probe.  The table key is as follow: yellow  deletion/probe inhibited/not available; red  deletion (<0.80); 
green or grey - normal copy number (0.8-1.3) and blue: amplification (>1.30). The graph represents the data shown in the table. X-axis  fragment length; Y-
axis - relative fluorescence units (RFU). There are 6 blue boxes around the probes with very high signals.  The median value of all probes per gene was used 
for statistical analysis. 
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Figure S1B 
Figure S1B  Data output of the same GC cell line mix used in figure 1A after the use of the competitor mixes following comparative analysis in Coffalyser 
Software. The column contains the sample name and the row has the information on copy number status per probe. Competitor mixes were used for KRAS 
and FGFR2. The table key is as follow: yellow probe fully inhibited/not available; red  deletion (<0.80); green or grey - normal copy number (0.8-1.3) and 
blue: amplification (>1.30). The graph represents the data shown in the table. X-axis  fragment length; Y-axis - relative fluorescence units (RFU). There was 
competitive inhibition of the probes that were previously very highly amplified (see supplementary Image 1A). There are 4 yellow boxes around probes that 
were fully inhibited and therefore do not have readable signal (represented in yellow in the table) and 3 red boxes around probes which have a very low 
signal (represented in red in the table). The median value of all probes per gene was used for statistical analysis. 
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Figure S1C 
 
Figure S1C  Data output of the same GC cell line mix used in figure 1A after the use of the competitor mixes following comparative analysis in Coffalyser 
Software. The column contains the sample name and the row has the information on copy number status per probe. A competitor mix was used for MYC. The 
table key is as follow: yellow probe fully inhibited/not available; red  deletion (<0.80); green or grey - normal copy number (0.8-1.3) and blue: amplification 
(>1.30). The graph represents the data shown in the table. X-axis  fragment length; Y-axis - relative fluorescence units (RFU). There was competitive 
inhibition of the probes that were previously very highly amplified (see supplementary image 1A). There are 2 red boxes around probes which have a very low 
signal (represented in red in the table). The median value of all probes per gene was used for statistical analysis. 
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Figure S1D 
 
Figure S1D  Data output of the same GC cell line mix used in figure 1A after the use of the competitor mixes following comparative analysis in Coffalyser 
Software. The column contains the sample name and the row has the information on copy number status per probe. A competitor mixes was used for ERBB2. 
The table key is as follow: yellow probe fully inhibited/not available; red  deletion (<0.80); green or grey - normal copy number (0.8-1.3) and blue: 
amplification (>1.30). The graph represents the data shown in the table. X-axis  fragment length; Y-axis - relative fluorescence units (RFU). There was 
competitive inhibition of the probes that were previously very highly amplified (See Supplementary Image 1A). There are 2 yellow boxes around the probes 
that were fully inhibited (represented in yellow in the table) and 1 red box around the probe with a very low signal (represented in red in the table). The 
median value of all probes per gene was used for statistical analysis. 
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Figure S2 
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Figure 2. Venn diagrams illustrating frequency of co-amplification of receptor tyrosine kinase genes (A) and downstream signalling genes (B) in the primary 
gastric cancer. Name of the gene at the top of each ellipse, frequency of gastric cancers with co-amplifications shown in the area where the ellipses intercept. 
 
 
 
  
  
 
Table S4.  
Comparison of the reported frequency of receptor tyrosine kinase co-amplification  
Co-amplification Current study n (%) Yk et al45 n (%) Liu et al46 n (%) Nagatsuma et al47 n (%) Deng et al9 n (%) 
ERBB2 and EGFR 11 (5%) 3 (4%) - 3 (0.3%) exclusive 
ERBB2 and MET 3 (1%) - 3 (2%) - exclusive 
ERBB2 and FGFR2 6 (3%) - exclusive - exclusive 
FGFR2 and MET  2 (1%) - 1(1%) - exclusive 
EGFR and MET 3 (1%) - - 3 (0.3%) exclusive 
 
Table S3. 
 MLPA gene  copy number status in primary gastric cancer tissue (n=237) and lymph node metastasis (n=103)  
 Primary GC LNmet Primary GC LNmet Primary GC LNmet Primary GC LNmet 
Deletion  
n (%) 
Deletion  
n (%) 
Normal 
 n (%) 
Normal  
n (%) 
Low level 
amplification n (%) 
Low level 
amplification n (%) 
High level 
amplification n (%) 
High level 
amplification n (%) 
R 
T 
K 
EGFR 4 (2) 1 (1) 208 (88) 97 (94) 20 (8) 2 (2) 5 (2) 3 (3) 
ERBB2 42 (18) 1 (1) 153 (64) 95 (92) 28 (12) 3 (3) 14 (6) 4 (4) 
FGFR2 2 (1) 1 (1) 211 (89) 95 (92) 19 (8) 4 (4) 5 (2) 3 (3) 
MET 42 (18) 6 (6) 184 (78) 95 (92) 10 (4) 2 (2) 1 (0) 0 (0) 
D 
S 
S 
PIK3CA 0 (0) 0 (0) 177 (75) 84 (82) 59 (25) 17 (17) 1 (0) 1 (1) 
KRAS 8 (3) 3 (3) 182 (77) 88 (86) 38 (16) 5 (4) 9 (4) 7 (7) 
MYC 14 (6) 1 (1) 179 (75) 75 (73) 38 (16) 25 (24) 6 (3) 2 (2) 
CCNE1 37 (16)  5 (5) 161 (68) 89 (86) 22 (9) 2 (2) 17 (7) 7 (7) 
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